Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers

The utilization of adjuvant chemotherapy after neoadjuvant chemotherapy in patients with high-risk residual disease is not frequent but might reduce the risk of recurrence. Participation in the ongoing adjuvant immunotherapy trials and development of other prospective studies are warranted to resolve this question.